Statins and SARS-CoV-2 Infection: Results of a Population-Based Prospective Cohort Study of 469 749 Adults From 2 Canadian Provinces

Background Small observational studies have suggested that statin users have a lower risk of dying with COVID-19. We tested this hypothesis in a large, population-based cohort of adults in 2 of Canada's most populous provinces: Ontario and Alberta. Methods and Results We examined reverse transc...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American Heart Association 2021-11, Vol.10 (21), p.e022330-e022330
Main Authors: McAlister, Finlay A, Wang, Ting, Wang, Xuesong, Chu, Anna, Goodman, Shaun G, van Diepen, Sean, Jackevicius, Cynthia A, Kaul, Padma, Udell, Jacob, Ko, Dennis T, Kwong, Jeffrey C, Austin, Peter C, Lee, Douglas S
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Alberta - epidemiology
COVID-19 - epidemiology
COVID‐19
Female
Hospitalization
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects
Intensive Care Units
Male
Middle Aged
Ontario - epidemiology
Original Research
outcomes
Prospective Studies
SARS‐CoV‐2
statins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Small observational studies have suggested that statin users have a lower risk of dying with COVID-19. We tested this hypothesis in a large, population-based cohort of adults in 2 of Canada's most populous provinces: Ontario and Alberta. Methods and Results We examined reverse transcriptase-polymerase chain reaction swab positivity rates for SARS-CoV-2 in adults using statins compared with nonusers. In patients with SARS-CoV-2 infection, we compared 30-day risk of all-cause emergency department visit, hospitalization, intensive care unit admission, or death in statin users versus nonusers, adjusting for baseline differences in demographics, clinical comorbidities, and prior health care use, as well as propensity for statin use. Between January and June 2020, 2.4% of 226 142 tested individuals aged 18 to 65 years, 2.7% of 88 387 people aged 66 to 75 years, and 4.1% of 154 950 people older than 75 years had a positive reverse transcriptase-polymerase chain reaction swab for SARS-CoV-2. Compared with 353 878 nonusers, the 115 871 statin users were more likely to test positive for SARS-CoV-2 (3.6% versus 2.8%,
ISSN:2047-9980
2047-9980
DOI:10.1161/JAHA.121.022330